Marex Group (MRX) – StreetInsider.com Reports
-
Marex Group (MRX) Opens At $19.50, IPO At $19
-
Marex Group (MRX) Prices 15.38M Share IPO at $19/sh
-
Marex Group (MRX) Launches 15.38M Share IPO
-
Marex Group (MRX) Announces 15.38M Share IPO at $18-$21/sh
-
UPDATE: Garmin (GRMN) to replace RR Donnelly in S&P 500
-
Valeant Pharma (VRX) Reaches Agreement with Galderma; Will Make Upfront Payment (MRX)
-
Valeant (VRX) Names Two New EVPs
-
Valeant (VRX) Receives FTC Clearance to Acquire Medicis Pharma (MRX)
-
Medicis (MRX) Slumps as Q-Med Takes Up Lawsuit (VRX)
-
Susquehanna Downgrades Medicis (MRX) to Neutral
-
Medicis Pharmaceutical Corp. (MRX) Declares $0.10 Quarterly Dividend; 0.9% Yield
-
Valeant Pharma (VRX) COO De Silva to Leave Company
-
Top 10 News Items 09/04 - 09/07: Where Are the Jobs?; Draghi Fires-Up Markets; Facebook CEO Pauses on Sales; Intel Issues Warning
-
Jefferies Maintains a 'Buy/Top Pick' on Valeant Pharmaceuticals (VRX); Taking the Right Medic(is)ine
-
Barclays Maintains an 'Equalweight' on Medicis (MRX); Is Another Bidder Out There?
-
Stifel Nicolaus Downgrades Medicis (MRX) to Hold
-
Goldman Sachs Downgrades Medicis (MRX) to Neutral; Limited Upside From Deal Now
-
Market Wrap: U.S. Manufacturing on the Ropes; One Week Until iPhone; Parcel Shippers Pinched
-
Barclays on Medicis (MRX)/Valeant (VRX) Deal: Surprise...or Not Really?
-
Piper Jaffray Downgrades Medicis (MRX) to Neutral after Takeover
-
RBC Capital Downgrades Medicis (MRX) to Sector Perform
-
Unusual 11 Mid-Day Movers 09/04: (MRX) (HEK) (CHTP) Higher; (DDMG) (MEG) (JRCC) Lower
-
Notable Mergers and Acquisitions of the Day 09/04: (VRX)/(MRX) (KND) (FORM) (NLP)
-
Pre-Open Movers 9/4: (MRX) (VRX) (STEM) Higher; (DDMG) (WLT) (ANR) Lower (more...)
-
Canaccord Genuity Maintains a 'Hold' on Medicis (MRX); Key Question Around Acquisition Is...
-
Cantor Fitzgerald Maintains a 'Hold' on Medicis (MRX); Acquisition Rewarding Patient Investors
-
Credit Suisse Upgrades Medicis (MRX) to Neutral
-
Valeant (VRX) to Acquire Medicis (MRX) to $44/Share; Deal Valued at $2.6B
-
Leerink Swann Starts Hyperion Therapeutics (HPTX) at Outperform; Attractive Opportunity in Orphan Drug Model
-
Canaccord Genuity Reiterates a 'Buy' on Solta Medical (SLTM); Follow-on Gives Push to MRX Milestone
-
Low Visibility Prompts Canaccord to Cut Price Target on Medicis (MRX)
-
Goldman Sach Cuts Price Target on Medicis (MRX)
-
Medicis Pharmaceutical Corp. (MRX) Tops Q2 EPS by 6c; Issues Light Q3, FY12 Outlook
-
Analyst Says Obagi (OMPI) Could Soon See Offers from 'Multiple Suitors'
-
Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX
-
Goldman Calls Medicis (MRX) 'One of the Most Likely M&A Targets' in Specialty Pharma Space
-
Paulson's Paulson & Co. Shows New Stakes in CZR, COV, HCA
-
Cantor Fitzgerald Maintains a 'Hold' on Medicis (MRX); Looking For The Accretive Transaction
-
Auriga Reiterates a 'Buy' on Medicis (MRX); Q1 Beat Underscores Execution
-
Medicis (MRX) Files Automatic Mixed Securities Shelf
-
Medicis Pharmaceutical Corp. (MRX) Tops Q1 EPS by 18c
-
Needham & Company Reiterates a 'Buy' on Solta Medical (SLTM); Good Quarter
-
Auriga Starts Medicis (MRX) at Buy; Favorable Risk/Reward Profile
-
Cantor Fitzgerald Maintains a 'Hold' on Medicis (MRX); Adjusting Numbers
-
Deutsche Bank Maintains a 'Buy' on Medicis (MRX) After In-Depth Meeting with Management
-
Canaccord Genuity Maintains a 'Hold' on Medicis (MRX); Taking A Deeper Look
-
Pre-Open Movers 3/9: (QSFT) (RENN) (MCP) Higher; (GMCR) (ZGNX) (BODY) Lower (more...)
-
Goldman Sachs Upgrades Medicis (MRX) to Buy, Focused on Growth
-
Goldman Sachs Downgrades Warner Chilcott (WCRX) to Neutral
-
Cantor Fitzgerald Raises Price Target on Medicis (MRX) But Remains Concerned
Back to MRX Stock Lookup